Eating Disorders

Primary Care Assessment and Management
  • Amy L. Clouse
Chapter
Part of the Current Clinical Practice book series (CCP)

Abstract

Eating disorders are among the most common psychiatric problems in the United States. Anorexia nervosa and bulimia nervosa in particular are associated with significant medical and psychiatric morbidity, with a mortality rate of 10%, the highest of all psychiatric disorders. Although primary care providers are often the first to identify patients with eating disorders, more than half of all cases go undiagnosed (1). Primary care providers can learn to recognize eating disorders, manage the medical complications as they develop, and know when to refer patients for additional treatment.

Keywords

Bone Mineral Density Anorexia Nervosa Eating Disorder Primary Care Provider Binge Eating 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.
This is a preview of subscription content, log in to check access.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Becker AE, Grinspoon SK, Klibanski A, Herzog DB. Eating disorders. N Engl J Med 1999;340:1092–1098.PubMedCrossRefGoogle Scholar
  2. 2.
    American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 4th ed., text revision. Washington, DC: American Psychiatric Association, 2000; pp. 583–594.Google Scholar
  3. 3.
    De Zwaan M. Binge eating disorder and obesity. Int J Obes Relat Metab Disord 2001;25(Suppl 1):S51–S55.PubMedCrossRefGoogle Scholar
  4. 4.
    Guarda AS, Redgrave GW. Eating disorders: detection, assessment, and treatment in primary care. Adv Stud Med 2004;4(9):468–475.Google Scholar
  5. 5.
    American Psychiatric Association Work Group on Eating Disorders. Practice guideline for the treatment of patients with eating disorders (revision). Am J Psychiatry 2000;157(Suppl l):1–39.Google Scholar
  6. 6.
    Dingemans AE, Bruna MJ, van Furth EF. Binge eating disorder: a review. Int J Obes 2002;26:299–307.CrossRefGoogle Scholar
  7. 7.
    Striegel-Moore RH, Dohm FA, Kraemer HC, et al. Eating disorders in white and black women. Am J Psychiatry 2003;160:1326–1331.PubMedCrossRefGoogle Scholar
  8. 8.
    Rubinstein S, Caballero B. Is Miss America an undernourished role model? JAMA 2000;283(12):1569.PubMedCrossRefGoogle Scholar
  9. 9.
    Martinez-Gonzalez MA, Gual P, Lahortiga F, et al. Parental factors, mass media influences and the onset of eating disorders in a prospective population-based cohort. Pediatrics 2003;111:315–320.PubMedCrossRefGoogle Scholar
  10. 10.
    Devlin MJ, Zhu AJ. Body image in the balance. JAMA 2001;286(17):2159.PubMedCrossRefGoogle Scholar
  11. 11.
    Mehler PS. Diagnosis and care of patients with anorexia nervosa in primary care settings. Ann Intern Med 2001;134:1048–1059.PubMedGoogle Scholar
  12. 12.
    Bulik CM, Tozzi F, Anderson C, et al. The relation between eating disorders and components of perfectionism. Am J Psychiatry 2003; 160:366–368.PubMedCrossRefGoogle Scholar
  13. 13.
    Pritts, SD, Susman J. Diagnosis of eating disorders in primary care. Am Fam Physician 2003;67:297–304.PubMedGoogle Scholar
  14. 14.
    Gorwood P, Kipman A, Foulon C. The human genetics of anorexia nervosa. Eur J Pharmacol 2003;480:163–170.PubMedCrossRefGoogle Scholar
  15. 15.
    Bulik CM, Sullivan PF, Kendler KS. Genetic and environmental contributions to obesity and binge eating. Int J Eat Disord 2003;33:293–298.PubMedCrossRefGoogle Scholar
  16. 16.
    Fairburn CG, Cowen PJ, Harrison PJ. Twin studies and the etiology of eating disorders. Int J Eat Disord 1999;26:349–358.PubMedCrossRefGoogle Scholar
  17. 17.
    Branson R, Potoczna N, Kral JG, et al. Binge eating as a major phenotype of melanocortin 4 receptior gene mutations. N Engl J Med 2003;348(12):1096–1103.PubMedCrossRefGoogle Scholar
  18. 18.
    Schmidt U, Tiller J, Blanchard M, et al. Is there a specific trauma precipitating anorexia nervosa? Psychol Med 1997;27:523–530.PubMedCrossRefGoogle Scholar
  19. 19.
    Mehler PS, Anderson AE, eds. Eating disorders: a guide to medical care and complications. Baltimore, MD. The Johns Hopkins University Press. 1999.Google Scholar
  20. 20.
    Herzog DB, Nussbaum KM, Marmor AK. Comorbidity and outcome in eating disorders. Psychiatr Clin North Am 1996;19(4):843–859.PubMedCrossRefGoogle Scholar
  21. 21.
    Morgan JF, Reid F, Lacey JH. The Scoff questionnaire: assessment of a new screening tool for eating disorders. BMJ 1999;318:1467–1468.Google Scholar
  22. 22.
    Cotton MA, Ball C, Robinson P. Four simple questions can help screen for eating disorders. J Gen Intern Med 2003;18:53–56.PubMedCrossRefGoogle Scholar
  23. 23.
    Devuyst O, Lambert M, Rodhain J, et al. Haematological changes and infectious complications in anorexia nervosa, a case control study. Q J Med 1993;86:791–799.PubMedGoogle Scholar
  24. 24.
    Mehler PS. Electrolyte disorders in bulimia. Eating disorders: The Journal of Treatment and Prevention 1998;6:65–68.Google Scholar
  25. 25.
    Croxson MS, Ibbertson HK. Low serum triiodothyronine (T3) and hypothyroidism in anorexia nervosa J Clin Endocrinol Metab 1977;44(1):167–174.PubMedCrossRefGoogle Scholar
  26. 26.
    Durakovic Z, Durakovic A, Korsic M. Changes of the corrected Q-T interval in the electrocardiogram of patients with anorexia nervosa. Int J Cardiol 1994;45:115–120.PubMedCrossRefGoogle Scholar
  27. 27.
    Fisler JS. Cardiac effects of starvation and semistarvation diets: safety and mechanisms of action. Am J Clin Nutr 1992;152:1073–1074.Google Scholar
  28. 28.
    Cooke RA, Chambers JB, Singh R, et al. QT interval in anorexia nervosa. British Heart J 1994;72:69–73.CrossRefGoogle Scholar
  29. 29.
    Oka Y, Ito T, Matsumoto S, et al. Mitral valve prolapse in patients with anorexia nervosa. Two-dimensional echocardiographic study. Jpn Heart J 1987;28:873–882.PubMedGoogle Scholar
  30. 30.
    Ho PC, Dweik R, Cohen MC. Rapidly reversible cardiomyopathy associated with chronic ipecac ingestion. Clin Cardiol 1998;21(10):780–783.PubMedCrossRefGoogle Scholar
  31. 31.
    Frideman EJ. Death from ipecac intoxication in a patient with anorexia nervosa. Am J Psychiatry 1984;141(5):702–703.Google Scholar
  32. 32.
    Swenne I. Heart risk associated with weight loss in anorexia nervosa and eating disorders. Acta Paediatr 2000;89(4):447–452.PubMedCrossRefGoogle Scholar
  33. 33.
    Marinella MA. Refeeding syndrome and hypophosphatemia. J Intensive Care Med 2005;20(3):155–159.PubMedCrossRefGoogle Scholar
  34. 34.
    Golden NH, Meyer W. Nutritional rehabilitation of anorexia nervosa. Goals and dangers. Int J Adolesc Med Health 2004;16(2):131–144.PubMedGoogle Scholar
  35. 35.
    McGilley BM, Pryor TL. Assessment and treatment of bulimia nervosa. Am Fam Phys 1998;57(11):2743–2750.Google Scholar
  36. 36.
    Little JW. Eating disorders: dental implications. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2002;93(2):138–143.PubMedCrossRefGoogle Scholar
  37. 37.
    Milosevic A, Brodie DA, Slade PD. Dental erosion, oral hygiene, and nutrition in eating disorders. Int J Eat Disord 1997;21(2):195–199.PubMedCrossRefGoogle Scholar
  38. 38.
    Kinzl J, Biebl W, Herold M. Significance of vomiting for hyperamylasemia and sialadenosis in patients with eating disorders. Int J Eat Disord 1993;13(1):117–124.PubMedCrossRefGoogle Scholar
  39. 39.
    Mehler PS, Wallace JA. Sialadenosis in bulimia. A new treatment. Arch Otolaryngol Head Neck Surg 1993;119(7):787–788.PubMedGoogle Scholar
  40. 40.
    Coleman H, Altini M, Nayler S, et al. Sialadenosis: a presenting sign in bulimia. Head Neck 1998;20(8):758–762.PubMedCrossRefGoogle Scholar
  41. 41.
    Benini L, Todesco T, Dalle Grave R, et al. Gastric emptying in patients with restricting and binge/purging subtypes of anorexia nervosa. Am J Gastroenterol 2004;99(8):1448–1454.PubMedCrossRefGoogle Scholar
  42. 42.
    Hadley SJ, Walsh BT. Gastrointestinal disturbances in anorexia nervosa and bulimia nervosa. Curr Drug Targets CNS Neurol Disord 2003;2(1):1–9.PubMedCrossRefGoogle Scholar
  43. 43.
    Chun AB, Sokol MS, Kaye WH, et al. Colonic and anorectal function in constipated patients with anorexia nervosa. Am J Gastroenterol 1997;92(10):1879–1883.PubMedGoogle Scholar
  44. 44.
    Szmukler GI, Young CP, Miller G, et al. A controlled trial of cisapride in anorexia nervosa. Int J Eat Disord 1995;17(4):347–357.PubMedCrossRefGoogle Scholar
  45. 45.
    Richter JE. Cisapride: Limited access and alternatives. Cleve Clin J Med 2000;67:471–472.PubMedGoogle Scholar
  46. 46.
    Furuta S, Ozawa Y, Maejima K, et al. Anorexia nervosa with severe liver dysfunction and subsequent critical complications. Intern Med 1999;38(7):575–579.PubMedCrossRefGoogle Scholar
  47. 47.
    Mendell DA, Logemann JA. Bulimia and swallowing: cause for concern. Int J Eat Disord 2001;30:252–258.PubMedCrossRefGoogle Scholar
  48. 48.
    Anderson L, Shaw JM, McCargar L. Physiological effects of bulimia nervosa on the gastrointestinal tract. Can J Gstroenterol 1997;11(5):451–459.Google Scholar
  49. 49.
    Gowen GF, Stoldt HS, Rosato FE. Five risk factors identify patients with gastroesophageal intussusception. Arch Surg 1999;134(12):1394–1397.PubMedCrossRefGoogle Scholar
  50. 50.
    Colton P, Woodside DB, Kaplan AS. Laxative withdrawal in eating disorders: treatment protocol and 3 to 20-month follow-up. Int J Eat Disord 1999;25(3):311–317.PubMedCrossRefGoogle Scholar
  51. 51.
    Mehler PS. Bulimia nervosa. N Engl J Med 2003;349(9):875–881.PubMedCrossRefGoogle Scholar
  52. 52.
    Golden NH, Shenker JR. Amenorrhea in anorexia nervosa. Neuroendocrine control of hypothalamic dysfunction. Int J Eat Disord 1994;16:53–60.PubMedCrossRefGoogle Scholar
  53. 53.
    Frisch RE, McArthur JW. Menstrual cycle: fatness as a determinant of minimum weight for height necessary of maintenance or onset. Science 1974;185:949–951.PubMedCrossRefGoogle Scholar
  54. 54.
    Golden NH, Jacobson MS, Schebendach J, et al. Resumption of menses in anorexia nervosa. Arch Pediatr Adolesc Med 1997;151:16–21.PubMedGoogle Scholar
  55. 55.
    Marcus R, Cann C, Madvig P, et al. Menstrual function and bone mass in elite women distance runners. Ann Int Med 1985;902:158–163.Google Scholar
  56. 56.
    Rome ES. Eating disorders. Obstet Gynecol Clin N Am 2003;30:353–377.CrossRefGoogle Scholar
  57. 57.
    Grinspoon S, Gulick T, Askari H, et al. Serum leptin levels in women with anorexia nervosa. J Clin Endocrinol Metab 1996;81:3861–3863.PubMedCrossRefGoogle Scholar
  58. 58.
    Mehler PS, Eckel RH, Donahoo WT. Leptin levels in restricting and purging anorectics. Int J Eat Disord 1999;26(2):189–194.PubMedCrossRefGoogle Scholar
  59. 59.
    Eckert ED, Pomeroy C, Raymond N, et al. Leptin in anorexia nervosa. J Clin Endocrinol Metab 1998;83:791–795.PubMedCrossRefGoogle Scholar
  60. 60.
    Kreitzer PM, Golden NH, Yoon DJ, et al. Leptin levels in amenorrheic versus normally menstruating nutritionally rehabilitated patients with anorexia nervosa. Ped Res 1997;21–6A.Google Scholar
  61. 61.
    Copeland PM, Sacks NR, Herzog DB. Longitudinal follow-up of amenorrhea in eating disorders. Psychosom Med 1995;57:121–126.PubMedGoogle Scholar
  62. 62.
    Lucas AR, Melton LJ 3rd, Crowson CS, et al. Long term fracture risk among women with anorexia nervosa: a population based cohort study. Mayo Clin Proc 1999;74:972–977.PubMedCrossRefGoogle Scholar
  63. 63.
    Herzog, W, Minne H, Deter C, et al. Outcome of bone mineral density in anorexia nervosa patients 11.7 years after first admission. J Bone Min Res 1993;8:597–605.CrossRefGoogle Scholar
  64. 64.
    Iketani T, Kiriike N, Nakanishi S, Nakasuji T. Effects of weight gain and resumption of menses on reduced bone density in patients with anorexia nervosa. Biol Psychiatry 1995;37(8):521–527.PubMedCrossRefGoogle Scholar
  65. 65.
    Klibanski A, Biller BM, Schoenfeld DA, et al. The effects of estrogen administration on trabecular bone loss in young women with anorexia nervosa. J Clin Endocrinol Metab 1995;80:898–904.PubMedCrossRefGoogle Scholar
  66. 66.
    Soyka LA, Grinspoon S, Levitsky LL, et al. The effects of anorexia nervosa on bone metabolism in female adolescents. J Clin Endocrinol Metab 1999;84:4489–4496.PubMedCrossRefGoogle Scholar
  67. 67.
    Klibanski A, Biller BM, O’Fallon WM, et al. The effects of estrogen administration on trabecular bone loss in young women with anorexia nervosa. J Clin Endocrinol Metab 1995;80:898–904.PubMedCrossRefGoogle Scholar
  68. 68.
    Ward A, Brown N, Treasure J. Persistent osteopenia after recovery from anorexia nervosa. Int J Eat Disord 1997;22:71–75.PubMedCrossRefGoogle Scholar
  69. 69.
    Hergenroeder AC. Bone minieralization, hypothalamic amenorrhea, and sex steroid therapy in female adolescents and young adults. J Pediatr 1995;126:683–689.PubMedCrossRefGoogle Scholar
  70. 70.
    Golden NH, Lanzkowsky L, Schebendach J, et al. The effect of estrogen-progestin treatment on bone mineral density in anorexia nervosa. J Pediatr Adolesc Gynecol 2002;15(3):135–143.PubMedCrossRefGoogle Scholar
  71. 71.
    Seeman E, Szmukler GI, Formica C, et al. Osteoporosis in anorexia nervosa: the influence of peak bone density, bone loss, oral contraceptive use, and exercise. J Bone Miner Res 1992;7(12):1467–1474.PubMedGoogle Scholar
  72. 72.
    Goebel G, Schweiger U, Kruger R, et al. Predictors of bone mineral density in patients with eating disorders. Int J Eat Disord 1999;25:143–150.PubMedCrossRefGoogle Scholar
  73. 73.
    Hotta M, Fukunda I, Sato K, et al. The relationship between bone turnover and body weight, serum insulin like growth factor and serum IGF-binding protein levels in patients with anorexia nervosa. J Clin Endocrinol Metab 2000;85(1):200–206.PubMedCrossRefGoogle Scholar
  74. 74.
    Birmingham CL, Goldner EM, Bakan R. Controlled trial of zinc supplementation in anorexia nervosa. Int J Eat Disord 1994;15:251–255.PubMedGoogle Scholar
  75. 75.
    Gordon CM, Grace E, Emans SJ, et al. Effects of oral dehydroepiandrosterone on bone density in young women with anorexia nervosa: a randomized trial. J Clin Endocrinol Metab 2002;87(11):4935–4941.PubMedCrossRefGoogle Scholar
  76. 76.
    Iketani T, Kiriike N, Murray, et al. Effect of menatetrenone (vitamin K2) treatment on bone loss in patients with anorexia nervosa. Psychiatry Res 2003;117(3):259–269.PubMedCrossRefGoogle Scholar
  77. 77.
    Grinspoon S, Thomas L, Miller K, et al. Effects of recombinant human IGF-I and oral contraceptive administration on bone density in anorexia nervosa. J Clin Endocrinol Metab 2002;87(6):2883–2891.PubMedCrossRefGoogle Scholar
  78. 78.
    Golden NH, Iglesias EA, Jacobson MS, et al. Alendronate for the treatment of osteopenia in anorexia nervosa: a randomized double-blind, placebo-controlled trial. J Clin Endocrinol Metab 2005;90(6):3279–3285.CrossRefGoogle Scholar
  79. 79.
    Mehler PS. Osteoporosis in anorexia: prevention and treatment. Int J Eat Disord 2003;33:113–126.PubMedCrossRefGoogle Scholar
  80. 80.
    Zipfel S, Seibel MJ, Lowe B, et al. Osteoporosis in eating disorders: a follow up study of patients with anorexia and bulimia nervosa. J Clin Endocrinol Metab 2001;86(11):5227–5233.PubMedCrossRefGoogle Scholar
  81. 81.
    Katzman DK, Lambe EK, Mikulis DJ, et al. Cerebral gray matter and white matter volume deficits in adolescent girls with anorexia nervosa. J Pediatr 1996;129:794–803.PubMedCrossRefGoogle Scholar
  82. 82.
    Kornreich L, Shapira A, Horev G, et al. CT and MR evaluation of the brain in patients with anorexia nervosa. AJNR Am J Neuroradiol 1991;12:1213–1216.PubMedGoogle Scholar
  83. 83.
    Golden NH, Ashtari M, Kohn MR, et al. Reversibility of cerebral ventricular enlargement in anorexia nervosa demonstrated by quantitative magnetic resonance imaging. J Pediatr 1996;128:296–301.PubMedCrossRefGoogle Scholar
  84. 84.
    Swayze VW II, Andersen A, Arndt S, et al. Reversibility of brain tissue loss in anorexia nervosa assessed with a computerized Talairach 3-D proportional grid. Psychol Med 1996;26:381–390.PubMedCrossRefGoogle Scholar
  85. 85.
    Kaye WH, Nagata T, Weltzin TE, et al. Double-blind placebo-controlled administration of fluoxetine in restricting-and restricting-purging-type anorexia nervosa. Biol Psychiatry 2001;49(7):644–652.PubMedCrossRefGoogle Scholar
  86. 86.
    Kaye WH, Weltzin TE, Hsu LK, Bulik CM. An open trial of fluoxetine in patients with anorexia nervosa. J Clin Psychiatry 1991;52(11):464–471.PubMedGoogle Scholar
  87. 87.
    Attia E, Haiman C, Walsh BT, Flater SR. Does fluoxetine augment the inpatient treatment of anorexia nervosa? Am J Psychiatry 1998;155(4):548–551.PubMedGoogle Scholar
  88. 88.
    Holtkamp K, Konrad K, Kaiser N, et al. A retrospective study of SSRI treatment in adolescent anorexia nervosa: insufficient evidence for efficacy. J Psychiatr Res 2005;39(3):303–310.PubMedCrossRefGoogle Scholar
  89. 89.
    Barbarich NC, McConaha CW, Gaskill J, et al. An open trial of olanzapine in anorexia nervosa. J Clin Psychiatry 2004;65(11):1480–1482.PubMedCrossRefGoogle Scholar
  90. 90.
    Powers PS, Santana CA, Bannon YS. Olanzapine in the treatment of anorexia nervosa: an open label trial. Int J Eat Disord 2002;32(2):146–154.PubMedCrossRefGoogle Scholar
  91. 91.
    Mondraty N, Birmingham CL, Touyz S, et al. Randomized controlled trial of olanzapine in the treatment of cognitions in anorexia nervosa. Australa Psychiatry 2005;13(1):72–75.Google Scholar
  92. 92.
    Mitchell JE, de Zwaan M, Roerig JL. Drug therapy for patients with eating disorders. Curr Drug Targets CNS Neurol Disord 2003;2(1):17–29.PubMedCrossRefGoogle Scholar
  93. 93.
    Powers PS, Santana C. Available pharmacological treatments for anorexia nervosa. Expert Opin Pharmacother 2004;5(11):2287–2292.PubMedCrossRefGoogle Scholar
  94. 94.
    Bacaltchuk J, Hay P. Antidepressants versus placebo for people with bulimia nervosa. Cochrane Database Syst Rev 2003;(4):CD003391.PubMedGoogle Scholar
  95. 95.
    Goldstein DJ, Wilson MG, Thompson VL, et al. Long-term fluoxetine treatment of bulimia nervosa. Fluoxetine Bulimia Nervosa Research Group. Br J Psychiatry 1995;166(5):660–666.PubMedCrossRefGoogle Scholar
  96. 96.
    Fluoxetine Bulimia Nervosa Collaborative Study Group. Fluoxetine in the treatment of bulimia nervosa: a multicenter, placebo controlled, double-blind trial. Arch Gen Psychiatry 1992;49:139–147.Google Scholar
  97. 97.
    Fung SM, Ferrill MJ. Treatment of bulimia nervosa with ondansetron. Ann Pharmacother 2001;35(10):1270–1273.PubMedCrossRefGoogle Scholar
  98. 98.
    Faris PL, Kim SW, Meller WH, et al. Effect of decreasing afferent vagal activity with ondansetron on symptoms of bulimia nervosa: a randomized, double-blind trial. Lancet 2000;355(9206):792–797.PubMedCrossRefGoogle Scholar
  99. 99.
    Felstrom A, Blackshaw S. Topiramate for bulimia nervosa with bipolar II disorder. Am J Psychiatry 2002;159:1246–1247.PubMedCrossRefGoogle Scholar
  100. 100.
    Hedges DW, Reimherr FW, Hoopes SP, et al. Treatment of bulimia nervosa with topiramate in a randomized, double-blind, placebo-controlled trial, part 2: improvement in psychiatric measures. J Clin Psychiatry 2003;64(12):1449–1454.PubMedCrossRefGoogle Scholar
  101. 101.
    Hoopes SP, Reimherr FW, Hedges DW, et al. Treatment of bulimia nervosa with topiramate in a randomized, double-blind, placebo-controlled trial, part 1: improvement in binge and purge measures. J Clin Psychiatry 2003;64(11):1335–1341.PubMedGoogle Scholar
  102. 102.
    El Giamal N, de Zwaan M, Bailer U, et al. Reboxetine in the treatment of bulimia nervosa: a report of seven cases. Int Clin Psychopharmacol 2000;15(6):351–356.PubMedCrossRefGoogle Scholar
  103. 103.
    Fassino S, Daga GA, Boggio S, et al. Use of reboxetine in bulimia nervosa: a pilot study. J Psychopharmacol 2004:18(3):423–428.PubMedCrossRefGoogle Scholar
  104. 104.
    Gelber D, Levine J, Belmaker RH. Effect of inositol on bulimia nervosa and binge eating. Int J Eat Disord 2001;29(3):345–348.PubMedCrossRefGoogle Scholar
  105. 105.
    Appolinario JC, McElroy SL. Pharmacological approaches in the treatment of binge eating disorder. Curr Drug Targets 2004;5(3):301–307.PubMedCrossRefGoogle Scholar
  106. 106.
    Appolinario JC, Bacaltchuk J, Sichieri R, et al. A randomized, double blind, placebo-controlled study of sibutramine in the treatment of binge eating disorder. Arch Gen Psychiatry 2003;60(11):1109–1116.PubMedCrossRefGoogle Scholar
  107. 107.
    McElroy SL, Shapira NA, Arnold LM, et al. Topiramate in the long-term treatment of binge-eating disorder associated with obesity. J Clin Psychiatry 2004;65(11):1463–1469.PubMedCrossRefGoogle Scholar
  108. 108.
    McElroy SL, Kotwal R, Hudson JI, et al. Zonisamide in the treatment of binge-eating disorder: an open-label, prospective trial. J Clin Psychiatry 2004;65(1):50–56.PubMedCrossRefGoogle Scholar
  109. 109.
    Hay P, Bacaltchuk J, Claudino A, et al. Individual psychotherapy in the outpatient treatment of adults with anorexia nervosa. Cochrane Database Syst Rev 2003;(4):CD003909.PubMedGoogle Scholar
  110. 110.
    Eisler I, Dare C, Russell GF, et al. Family and individual therapy in anorexia nervosa. A 5-year follow-up. Arch Gen Psychiatry 1997;54(11):1025–1030.PubMedGoogle Scholar
  111. 111.
    Robin AL, Siegel PT, Moye AW, et al. A controlled comparison of family versus individual therapy for adolescents with anorexia nervosa. J Am Acad Child Adolesc Psychiatry 1999;38(12):1482–1489.PubMedCrossRefGoogle Scholar
  112. 112.
    Kleifield EI, Wagner S, Halmi KA. Cognitive-behavioral treatment of anorexia nervosa. Psychiatr Clin North Am 1996;19(4):715–737.PubMedCrossRefGoogle Scholar
  113. 113.
    Pike KM, Walsh BT, Vitousek K, et al. Cognitive behavior therapy in the posthopitalization treatment of anorexia nervosa. Am J Psychiatry 2003;160(11):2046–2049.PubMedCrossRefGoogle Scholar
  114. 114.
    Hay PJ, Bacaltchuk J, Stefano S. Psychotherapy for bulimia nervosa and binging. Cochrane Database Syst Rev 2004;(3):CD000562.PubMedGoogle Scholar
  115. 115.
    Agras WS, Walsh T, Fairburn CG, et al. A multicenter comparison of cognitive-behavioral therapy and interpersonal psychotherapy for bulimia nervosa. Arch Gen Psychiatry 2000;57:459–466.PubMedCrossRefGoogle Scholar
  116. 116.
    Bacaltchuk J, Hay P, Trefigli R. Antidepressants versus psychological treatments and their combination for bulimia nervosa. Cochrane Database Syst Rev 2001;(4):CD003385.PubMedGoogle Scholar
  117. 117.
    Mitchell JE, Halmi K, Wilson GT, et al. A randomized secondary treatment study of women with bulimia nervosa who fail to respond to CBT. Int J Eat Disord 2002;32(3):271–281.PubMedCrossRefGoogle Scholar
  118. 118.
    Herzog DB, Nussbaum KM, Marmor AK. Comorbidity and outcome in eating disorders. Psychiatr Clin North Am 1996;19:843–859.PubMedCrossRefGoogle Scholar
  119. 119.
    Steinhausen HC, Rauss-Mason C, Seidel R. Follow-up studies of anorexia nervosa: a review of four decades of outcome research. Psychol Med 1991;21:447–454.PubMedCrossRefGoogle Scholar
  120. 120.
    Herzog D, Keller M, Lavori P, Sacks N. The course and outcome of bulimia nervosa. J Clin Psychiatry 1991;52(Suppl):4–8.PubMedGoogle Scholar
  121. 121.
    Fairburn CG, Cooper Z, Doll HA. The natural course of bulimia nervosa and binge eating disorder in young women. Arch Gen Psychiatry 2000;57:659–665.PubMedCrossRefGoogle Scholar

Copyright information

© Humana Press Inc., Totowa, NJ 2008

Authors and Affiliations

  • Amy L. Clouse
    • 1
  1. 1.Family Medicine Residency ProgramAbington Memorial HospitalAbington

Personalised recommendations